Is the Combination of Pharmacokinetic and Pharmacodynamic Monitoring of Infliximab-Treated Patients the Way Forward?

TY - JOUR

T1 - Is the Combination of Pharmacokinetic and Pharmacodynamic Monitoring of Infliximab-Treated Patients the Way Forward?

AU - Queiroz, Natália Sousa Freitas

AU - Charabaty, Aline

N1 - Funding Information: Conflicts of interest The authors disclose the following: Natália Sousa Freitas Queiroz has received consulting fees from Janssen, lecture fees from Janssen, Takeda, UCB and AbbVie, and travel grant support from Takeda, Janssen, and AbbVie; and Aline Charabaty has received consulting fees from Janssen, Takeda, and AbbVie. Funding Information: Conflicts of interest The authors disclose the following: Nat?lia Sousa Freitas Queiroz has received consulting fees from Janssen, lecture fees from Janssen, Takeda, UCB and AbbVie, and travel grant support from Takeda, Janssen, and AbbVie; and Aline Charabaty has received consulting fees from Janssen, Takeda, and AbbVie.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85090059665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090059665&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2020.02.029

DO - 10.1016/j.cgh.2020.02.029

M3 - Letter

C2 - 32092397

AN - SCOPUS:85090059665

SN - 1542-3565

VL - 18

SP - 2631

EP - 2632

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 11

ER -